Background: Use of aspirin plus thienopyridine increases bleeding risk of coronary artery bypass graft (CABG) surgery. In STOP-CABG trial we prospectively evaluated the association between the pre-operative platelet function testing by different assay methods on the occurrence of post CABG bleeding. Methods: 81 patients undergoing CABG within 5 days of thienopyridine discontinuation were prospectively enrolled. On-treatment platelet reactivity was measured with Verify Now ( Conclusions: On-treatment platelet reactivity testing performed on the day of CABG surgery is able to predict the occurrence of post-operative IHMB. This may help clinicians to better manage the timing of CABG after thenopyridine cessation. Conclusions: These data prove that in patients affected by VHD and CAD hybrid strategies are safe and may improve outcomes compared to standard surgery, even in higher risk patients undergoing TAVR. Thus, we suggest a more extensive use of PCI combined with valve surgery. Furthermore, we suggest a revision of the current risk scores, as they were designed upon populations treated with conventional surgery and can't fit these new, evolving scenarios.
TCT-123
Incidence Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY Background: Acute kidney injury (AKI) is a well-recognized predictor of morbidity and mortality following PCI. However, the impact of AKI on the outcome of patients with acute coronary syndromes (ACS) undergoing coronary artery bypass graft surgery (CABG) has not been established. Methods: Of the 17,421 patients who presented with non-ST-segment elevation ACS or ST-segment elevation myocardial infarction (STEMI) enrolled in the ACUITY and the HORIZONS-AMI trials, 1,406 (8.0%) underwent CABG as principal treatment after coronary angiography. Endpoints were measured at 1 month and 1 year and included death, MI and ischemia-driven target vessel revascularization (TVR). Results: AKI occurred during hospital admission in 449 (31.9%) of the 1,406 patients treated with CABG. Patients with vs. without AKI had 1-month and 1-year mortality of 6.7% vs. 2.2%, p< 0.0001, and 10.4% vs. 4.3%, p< 0.0001, respectively. Patients with vs. without AKI had 1-month and 1-year composite major adverse cardiac events (MACE; death, MI or TVR) of 21.2% vs. 14.8%, p¼0.003, and 22.0% vs. 15.3%, p¼0.002, respectively. By multivariable analysis, after adjustment for age, gender, race, diabetes, hypertension, and baseline creatinine clearance, AKI was an independent predictor of mortality (overall and cardiac-related), as well as MACE at both 1 month and 1 year following CABG (Figure) .
Conclusions: AKI occurs in w1 of every 3 patients with ACS treated with CABG, and is a powerful independent predictor of death and MACE. These data highlight the need for AKI prevention strategies in patients undergoing CABG. 
